FDA clears OTC glucose monitoring system for weight administration

The U.S. Meals and Drug Administration has cleared the Signos Glucose Monitoring System, an over-the-counter glucose monitoring system for weight administration.

Signos integrates the Stelo by Dexcom glucose biosensor with a synthetic intelligence-driven platform to indicate how meals, exercise, stress, sleep, and timing have an effect on the physique in actual time—empowering individuals to make customized, biology-backed well being choices.

Key options of the monitoring system embody customized metabolic steering that makes use of the physique’s personal indicators and synthetic intelligence-driven insights to assist customers enhance sleep, handle weight, and decrease persistent illness threat. The system interprets real-time glucose fluctuations into easy, customized suggestions for more healthy day by day habits and tracks and connects responses to meals, train, sleep, and stress.

Clients can subscribe to Signos with a three-month plan for $139 per thirty days or a six-month plan for $129 per thirty days. The corporate supplies all vital steady glucose displays for the chosen plan length.

In line with the U.S. Facilities for Illness Management and Prevention, 73.6% of U.S. adults are categorised as having obese or weight problems. With the outcomes of the International Burden of Illness Research 2021 projecting diabetes diagnoses will attain 1.3 billion by 2050, the dimensions of the metabolic well being disaster is quickly accelerating.

“That is greater than a product launch—it is a mission,” Sharam Fouladgar-Mercer, CEO and founding father of Signos, stated in a press release. “Everybody deserves entry to insights that assist them reside more healthy, longer, extra vibrant lives. Signos is not nearly information; it is about giving individuals possession over their well being and weight journeys in a method by no means earlier than seen.”

Copyright © 2025 HealthDay. All rights reserved.